Literature DB >> 27733504

Mechanistic determinants of MBNL activity.

Łukasz J Sznajder1, Michał Michalak2, Katarzyna Taylor3, Piotr Cywoniuk3, Michał Kabza4, Agnieszka Wojtkowiak-Szlachcic3, Magdalena Matłoka3, Patryk Konieczny3, Krzysztof Sobczak5.   

Abstract

Muscleblind-like (MBNL) proteins are critical RNA processing factors in development. MBNL activity is disrupted in the neuromuscular disease myotonic dystrophy type 1 (DM1), due to the instability of a non-coding microsatellite in the DMPK gene and the expression of CUG expansion (CUGexp) RNAs. Pathogenic interactions between MBNL and CUGexp RNA lead to the formation of nuclear complexes termed foci and prevent MBNL function in pre-mRNA processing. The existence of multiple MBNL genes, as well as multiple protein isoforms, raises the question of whether different MBNL proteins possess unique or redundant functions. To address this question, we coexpressed three MBNL paralogs in cells at equivalent levels and characterized both specific and redundant roles of these proteins in alternative splicing and RNA foci dynamics. When coexpressed in the same cells, MBNL1, MBNL2 and MBNL3 bind the same RNA motifs with different affinities. While MBNL1 demonstrated the highest splicing activity, MBNL3 showed the lowest. When forming RNA foci, MBNL1 is the most mobile paralog, while MBNL3 is rather static and the most densely packed on CUGexp RNA. Therefore, our results demonstrate that MBNL paralogs and gene-specific isoforms possess inherent functional differences, an outcome that could be enlisted to improve therapeutic strategies for DM1.
© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27733504      PMCID: PMC5137450          DOI: 10.1093/nar/gkw915

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  58 in total

1.  Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1.

Authors:  Catherine Z Chen; Krzysztof Sobczak; Jason Hoskins; Noel Southall; Juan J Marugan; Wei Zheng; Charles A Thornton; Christopher P Austin
Journal:  Anal Bioanal Chem       Date:  2012-01-05       Impact factor: 4.142

2.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

Authors:  A Mankodi; E Logigian; L Callahan; C McClain; R White; D Henderson; M Krym; C A Thornton
Journal:  Science       Date:  2000-09-08       Impact factor: 47.728

3.  Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells.

Authors:  Majid Fardaei; Mark T Rogers; Helena M Thorpe; Kenneth Larkin; Marion G Hamshere; Peter S Harper; J David Brook
Journal:  Hum Mol Genet       Date:  2002-04-01       Impact factor: 6.150

4.  Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.

Authors:  Rahul N Kanadia; Jihae Shin; Yuan Yuan; Stuart G Beattie; Thurman M Wheeler; Charles A Thornton; Maurice S Swanson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

5.  Conserved developmental alternative splicing of muscleblind-like (MBNL) transcripts regulates MBNL localization and activity.

Authors:  Fulvia Terenzi; Andrea N Ladd
Journal:  RNA Biol       Date:  2010-01-21       Impact factor: 4.652

6.  Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins.

Authors:  Eric T Wang; Neal A L Cody; Sonali Jog; Michela Biancolella; Thomas T Wang; Daniel J Treacy; Shujun Luo; Gary P Schroth; David E Housman; Sita Reddy; Eric Lécuyer; Christopher B Burge
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

7.  RNA Bind-n-Seq: quantitative assessment of the sequence and structural binding specificity of RNA binding proteins.

Authors:  Nicole Lambert; Alex Robertson; Mohini Jangi; Sean McGeary; Phillip A Sharp; Christopher B Burge
Journal:  Mol Cell       Date:  2014-05-15       Impact factor: 17.970

8.  Identification of MBNL1 and MBNL3 domains required for splicing activation and repression.

Authors:  Ioannis Grammatikakis; Young-Hwa Goo; Gloria V Echeverria; Thomas A Cooper
Journal:  Nucleic Acids Res       Date:  2010-11-24       Impact factor: 16.971

9.  DDX6 regulates sequestered nuclear CUG-expanded DMPK-mRNA in dystrophia myotonica type 1.

Authors:  Olof J Pettersson; Lars Aagaard; Diana Andrejeva; Rune Thomsen; Thomas G Jensen; Christian K Damgaard
Journal:  Nucleic Acids Res       Date:  2014-05-03       Impact factor: 16.971

10.  Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.

Authors:  Marzena Wojciechowska; Katarzyna Taylor; Krzysztof Sobczak; Marek Napierala; Wlodzimierz J Krzyzosiak
Journal:  RNA Biol       Date:  2014-04-24       Impact factor: 4.652

View more
  31 in total

Review 1.  Repeat-associated RNA structure and aberrant splicing.

Authors:  Melissa A Hale; Nicholas E Johnson; J Andrew Berglund
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-16       Impact factor: 4.490

2.  Aberrant Expression of a Non-muscle RBFOX2 Isoform Triggers Cardiac Conduction Defects in Myotonic Dystrophy.

Authors:  Chaitali Misra; Sushant Bangru; Feikai Lin; Kin Lam; Sara N Koenig; Ellen R Lubbers; Jamila Hedhli; Nathaniel P Murphy; Darren J Parker; Lawrence W Dobrucki; Thomas A Cooper; Emad Tajkhorshid; Peter J Mohler; Auinash Kalsotra
Journal:  Dev Cell       Date:  2020-02-27       Impact factor: 12.270

Review 3.  Myotonic dystrophy: approach to therapy.

Authors:  Charles A Thornton; Eric Wang; Ellie M Carrell
Journal:  Curr Opin Genet Dev       Date:  2017-04-01       Impact factor: 5.578

4.  Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy.

Authors:  Matthew K Tanner; Zhenzhi Tang; Charles A Thornton
Journal:  Nucleic Acids Res       Date:  2021-02-26       Impact factor: 16.971

5.  Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein with high affinity for expanded CUG repeats.

Authors:  Ludovic Arandel; Magdalena Matloka; Arnaud F Klein; Frédérique Rau; Alain Sureau; Michel Ney; Aurélien Cordier; Maria Kondili; Micaela Polay-Espinoza; Naira Naouar; Arnaud Ferry; Mégane Lemaitre; Séverine Begard; Morvane Colin; Chloé Lamarre; Hélène Tran; Luc Buée; Joëlle Marie; Nicolas Sergeant; Denis Furling
Journal:  Nat Biomed Eng       Date:  2022-02-10       Impact factor: 25.671

6.  Pharmacotherapy alleviates pathological changes in human direct reprogrammed neuronal cell model of myotonic dystrophy type 1.

Authors:  Mougina K Eltahir; Masayuki Nakamori; Satoshi Hattori; Takashi Kimura; Hideki Mochizuki; Seiichi Nagano
Journal:  PLoS One       Date:  2022-07-01       Impact factor: 3.752

7.  Intron retention induced by microsatellite expansions as a disease biomarker.

Authors:  Łukasz J Sznajder; James D Thomas; Ellie M Carrell; Tammy Reid; Karen N McFarland; John D Cleary; Ruan Oliveira; Curtis A Nutter; Kirti Bhatt; Krzysztof Sobczak; Tetsuo Ashizawa; Charles A Thornton; Laura P W Ranum; Maurice S Swanson
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-02       Impact factor: 11.205

8.  MBNL expression in autoregulatory feedback loops.

Authors:  Patryk Konieczny; Ewa Stepniak-Konieczna; Krzysztof Sobczak
Journal:  RNA Biol       Date:  2017-11-13       Impact factor: 4.652

9.  Disrupted prenatal RNA processing and myogenesis in congenital myotonic dystrophy.

Authors:  James D Thomas; Łukasz J Sznajder; Olgert Bardhi; Faaiq N Aslam; Zacharias P Anastasiadis; Marina M Scotti; Ichizo Nishino; Masayuki Nakamori; Eric T Wang; Maurice S Swanson
Journal:  Genes Dev       Date:  2017-07-11       Impact factor: 11.361

10.  Hybrid splicing minigene and antisense oligonucleotides as efficient tools to determine functional protein/RNA interactions.

Authors:  Piotr Cywoniuk; Katarzyna Taylor; Łukasz J Sznajder; Krzysztof Sobczak
Journal:  Sci Rep       Date:  2017-12-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.